Policy & Regulation

The same United States House of Representatives that voted to let Veterans Administration doctors help vets access medical cannabis also voted, nearly simultaneously, to block the federal rescheduling process that would make such access legally coherent. That is not mixed signals; it is a fractured federal posture. For the roughly 9 million veterans enrolled in VA healthcare, it lands with consequences that are anything but abstract.

Federal efforts to reschedule cannabis typically are framed as a matter of drug policy, centering on taxation, criminal enforcement, and the plant’s classification under the Controlled Substances Act. Yet, this traditional framing increasingly obscures a deeper regulatory transformation. As a partial shift to Schedule III lowers long-standing barriers to genetic research, cannabis is rapidly entering the agricultural biotechnology era. This scientific leap is setting up an unprecedented collision with an unsettled federal oversight landscape. Regulators must now confront whether advanced cannabis innovations will be governed solely as controlled substances or treated as genetically modified crops subject to complex agricultural pest risk oversight.

The move to reschedule cannabis is facing its first major judicial test. Following a lawsuit by Smart Approaches to Marijuana (SAM), the industry is left wondering if the shift to Schedule III is in jeopardy. While the April 23 order remains in effect for now, the legal challenge introduces new layers of uncertainty for medical and adult-use operators alike. To maintain stability, companies must look beyond the headlines. We break down the two critical factors that will determine whether federal relief arrives on time or hits a roadblock.

The DEA has launched a portal for state-licensed medical cannabis registration, offering a rare path to federal legitimacy. However, with House Republicans moving to bottle up broader rescheduling and a 60-day window closing fast, operators face both a race for federal protection and an increasingly uncertain climate in D.C.

The Department of Justice moving cannabis from Schedule I to Schedule III is a historic shift, but it isn’t a universal fix. From the multi-million-dollar 280E tax opportunity to the ongoing hurdles for adult-use operators, we break down the real business impact of the 2026 rescheduling order and why federal oversight is about to get a lot more complex.

The DEA isn’t stepping back; it’s stepping in. While the industry celebrates the end of 280E, the fine print of the new Schedule III order reveals a mandatory federal middleman, undisclosed fees, and a legal “prescription” trap that could leave dispensaries in limbo. Here is what the rescheduling order actually means for your bottom line.

A significant shift in federal law via H.R. 5371 threatens to recriminalize most hemp-derived THC products by November 12, 2026. Dubbed the “hemp-killing clause,” this provision sets a 0.4mg total THC cap per container, potentially turning compliant businesses into “real estate time bombs.” From auditing leases to negotiating early termination rights, two attorneys tackle how hemp tenants and landlords can navigate the looming regulatory crisis and protect their commercial interests before the “Hemp D-Day” deadline.

A potential move of cannabis to Schedule III could eventually reshape the industry’s tax burden by ending the reach of Section 280E. But operators should not confuse political momentum with immediate relief. A CPA explains why retroactive tax refunds are unlikely and disciplined compliance still matters. From defensible cost accounting to scenario planning and entity-structure review, the smartest path is cautious preparation rather than reactive change.

CDTFA reports California collected $255.1M in Q4 2025 cannabis taxes, down after Q3’s temporary rate spike.

According to a new report from Americans for Safe Access, impending federal changes to hemp definitions could strip access from veterans, seniors, and those with rare diseases who rely on full-spectrum products.